|
|
|
|
|
|
|
Biol Blood Marrow Transplant 2010,Sep,01;16(9):1315-23; (PMID: 20353831)
[...] between donor and recipient is not considered a barrier to successful allogeneic hematopoietic stem cell transplantation (HSCT), even if it can be associated with several immunohematologic complications. Nevertheless, conflicting data still exist as to its influence on [...]; P = .055), but this was not confirmed in multivariate analysis. In patients with acute leukemia, multivariate analysis revealed an association between major ABO mismatch and decreased relapse rate with borderline statistical significance (hazard ratio, 0.65; P = .04).[...]Somewhat surprisingly, the graft-versus-plasma cell effect seems to be confined to this stem cell source.
|
|
|
Leuk Res 2010,Sep,01;34(9):1111-8; (PMID: 20472288)
[...]) is an incurable disease characterized by the accumulation of malignant plasma cells in the bone marrow. Recently, an improved understanding of the biology of the disease has led to the development of [...]MM remains incurable. The combination of bortezomib and an HDAC inhibitor synergistically induces MM cell apoptosis and may be of value in the treatment of patients with relapsed/refractory MM.[...]
|
|
|
Am J Clin Pathol 2010,Sep,01;134(3):429-35; (PMID: 20716799)
[...] biopsy specimens, including normal marrow specimens and cases of myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, plasma cell neoplasm, and metastatic carcinoma. Immunoreactivity for CD71 was restricted to erythroid precursors in normal and dyspoietic [...]
|
|
|
Leuk Res 2010,Aug,01;34(8):1103-6; (PMID: 20363025)
B-cell lines of diverse neoplastic origin express the serotonin transporter (SERT/SLC6A4) and growth arrest in response to SERT-ligands, including the antidepressants chlomipramine and [...]
|
|
|
Leuk Res 2010,Aug,01;34(8):1007-11; (PMID: 20096458)
[...]MM) was investigated in two populations of B-cell lineage: B-cells and plasma cells (PCs). Using immunofluorescent staining, it was shown that CA in B-cells is present in 3.2+/-2.5% in healthy donors versus 9.9+/-7.9% in [...]
|
|
|
Cancer Genet Cytogenet 2010,Aug,01;201(1):62-5; (PMID: 20633772)
[...]The IGH/CCND1 fusion gene has been reported in many hematologic tumors such as mantle cell lymphoma, chronic lymphocytic leukemia, prolymphocytic leukemia, multiple myeloma, and plasma cell leukemia. We report a case of plasma cell leukemia showing five IGH/CCND1 fusion signals by [...]
|
|
|
Anticancer Drugs 2010,Aug,01;21(7):695-703; (PMID: 20629201)
[...], a selective inhibitor of c-KIT and Bcr-Abl tyrosine kinases, approved for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors, shows further therapeutic potential for gliomas, glioblastoma, renal[...]gastrointestinal stromal tumors, shows further therapeutic potential for gliomas, glioblastoma, renal cell carcinoma, autoimmune nephritis and other neoplasms. It is metabolized by CYP3A4, is highly bound to alpha-1-acid glycoprotein and is a P-glycoprotein substrate limiting its [...] PO (50 mg/kg) alone or co-administered with primaquine (12.5 mg/kg), ketoconazole (50 mg/kg) or both, and imatinib concentration in the plasma, kidney, liver and brain was measured at prescheduled time points by HPLC. Noncompartmental pharmacokinetic parameters were estimated.[...]
|
|
|
Leuk Lymphoma 2010,Aug,01;51(8):1543-9; (PMID: 20528248)
[...] using microarray analysis of plasma cell samples, separated according to the number of expressed CTs; (2) examine possible pathways related to MM pathogenesis; (3) validate the expression of candidate genes by quantitative real-time PCR (RQ-PCR).[...]
|
|
|
Mol Cancer Ther 2010,Aug,01;9(8):2243-54; (PMID: 20682657)
[...] with aberrant CDK activation, the retinoblastoma protein (pRb) pathway is deregulated, leading to uncontrolled cell proliferation. Constitutive activation of TRKs is instead linked to cancer cell survival and dissemination. Here, we show that the novel small-molecule PHA-848125, a potent dual inhibitor of CDKs and TRKs, possesses significant antitumor activity.[...], PHA-848125 has significant antitumor activity in various human xenografts and carcinogen-induced tumors as well as in disseminated primary leukemia models, with plasma concentrations in rodents in the same range as those found active in inhibiting cancer cell proliferation. Mechanism of action was also confirmed in vivo as assessed in tumor biopsies from treated [...]
|
|
|
Br J Haematol 2010,Aug,01;150(4):418-27; (PMID: 20701603)
Extramedullary plasma cell cancers, such as plasma cell leukaemia (PCL) and multiple extramedullary plasmacytomas (MEP) are very aggressive malignancies.[...]
|
 1 2 3 4 5 6 7 8 
|
|
|
|
|
